Research is an important component of our program, allowing us to maintain the highest levels of care. Making research a priority can create advancements in medical treatment within a child’s lifetime. Through our partnership with DaVita, access to dialysis-specific data allows us to evaluate quality in unique ways to improve our program and produce the best outcomes for our patients. DaVita also partners with selected, high-quality pediatric hospitals around the country, which allows Lurie Children’s to be the leader of a national pediatric program that relies on outcomes-based research. Working with this research-powered group will help us continually adapt our dialysis treatment to best fit children’s needs.
Pediatric dialysis prescriptions are usually based on adult standards, not tailored to body surface area, which can lead to underdialysis in our patients. Our research has shown that dialysis calculated using body surface area is a more effective method for treating children. Therefore, we’ve based our pediatric dialysis program on the results of that study, leading to excellent outcomes.
At Lurie Children’s, we not only treat those children with irreversible loss of kidney function, but those children in whom a temporary loss of kidney function termed acute kidney injury (AKI) occurs. As a result, we have partnered with the Heart Center’s cardiac care intensivists in the Regenstein Cardiac Care Unit (CCU) and Lefkofsky Pediatric Intensive Care Unit (PICU), in addition to other areas in the hospital, to identify patients that may be at risk for AKI so we can proactively treat them and help prevent serious complications.
Often, children with AKI need continuous renal replacement therapy (CRRT) and we offer state-of-the-art CRRT through our partnership with DaVita. We offer CRRT around-the-clock so that we can provide the best possible care to our patients.
For other, special medical conditions, we also provide innovative care including plasmapheresis for many auto-immune disorders including myasthenia gravis, and lipopheresis, for inborn errors of cholesterol metabolism, each through our partnership with DaVita.
